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1An ideal dosage regimen in the drug therapy of any disease is the one,
which immediately attains the desire therapeutics concentration of drug in plasma
(or  at  the  site  of  action)  and  maintains  it  constant  for  the  entire  duration  of
treatment1.
Drugs are frequently taken by oral administration. Although a few drugs
taken orally are intended to be dissolved within the mouth, majority of drugs taken
orally are swallowed. Compared with alternate routes, the oral route of drug
administration is the most popular and has been successfully used for conventional
delivery of drug. It is considered as most natural, convenient means of administering
drugs2.
One important drawback of these dosage forms was many patients have
difficulty in swallowing tablets and hard gelatin capsules and consequently do not
take medications as prescribed. It is estimated that 50% of the population is affected
by this problem, which results in a high incidence of noncompliance and ineffective
therapy3. It has been reported that dysphagia (difficulty in swallowing) is common
among all age groups and more specific with pediatric, geriatric population along
with institutionalized patients and patients with nausea4.
         This  problem  can  be  resolved  by  the  creation  of  rapidly  dispersing  or
dissolving oral forms, which do not require water to aid swallowing. The dosage
forms are placed in the mouth, allowed to disperse or dissolve in the saliva, and then
are swallowed in the normal way3.
1.1 Oral Dispersible Tablet
This is an innovative tablet technology where the dosage form containing
active pharmaceutical ingredients disintegrates rapidly, usually in a matter of
seconds, without the need for water, providing optimal convenience to the patient.
Innovators and inventor companies have given these tablets various names such as
Orally  disintegrating  tablets  (ODT),  Mouth  dissolving  (MD),  Fast  melting,  Fast
2dissolving, Fast dispersing, Rapid dissolve,Rapid melt, Quick disintegrating,
Rapimelts, Melt-in-mouth tablets, Porous tablets or Orodisperse 5, 6.
British Pharmacopoeia defines oral dispersible tablets as uncoated tablets
intended  to  be  placed  in  the  mouth  were  they  disperse  rapidly  before  being
swallowed7.
1.2 Criteria for developing Oral Dispersible Tablets 5, 8, 9
Tablets should
? Not require water to swallow, and should disintegrate or dissolve in
mouth in matter of seconds.
? Have an acceptable taste masking.
? Leave minimal or no residue in mouth after administration.
? Have a pleasant mouth feel.
? Be less sensitive to environmental conditions such as temperature and
humidity.
1.3 Salient features of Oral Dispersible Tablets 5, 9
? Do not require water to swallow, which is convenient during
travelling and who do not have immediate access to water.
? Ease of administration to the patients who are unable to swallow,
such as bedridden patients, stroke victims and patients who refuse to
swallow such as geriatric, pediatric & psychiatric patients.
? Some drugs may be absorbed from the mouth, pharynx and
esophagus as the saliva passes down into stomach in those cases
bioavailability of the drug is increased.
? The risk of suffocation during oral administration of conventional
tablet due to physical obstruction is avoided.
3? Good mouth feel property helps to change the perception of
medication as bitter pill.
1.4 Benefits of Oral Dispersible Tablets 5, 10
? Administered without water anywhere and anytime.
? Suitability for geriatric, pediatric, and bedridden or developmentally
disabled patients, patients with persistent nausea.
? Beneficial in cases such as motion sickness, sudden episodes of
allergic attack or coughing, where an ultra rapid onset of action
required.
? An increased bioavailability, particularly in cases of insoluble and
hydrophobic drugs, due to rapid disintegration and dissolution of
these tablets.
? Stability for longer duration of time, since the drug remains in solid
dosage  form  till  it  is  consumed.  So,  it  combines  advantage  of  solid
dosage form in terms of stability and liquid dosage form in terms of
bioavailability.
1.5 Limitations of Oral Dispersible Tablets 5, 8, 9, 10
o The tablets usually have low mechanical strength, so they are friable
or brittle and difficult to handle. So they require specialized peel-off
blister packing and careful handling.
o The tablets may leave unpleasant taste and/or grittiness in mouth if
not formulated properly.
o Drugs with relatively large doses are difficult to formulate into oral
dispersible tablets.
4o Patients with Sjogren’s syndrome or dryness of mouth due to
decreased saliva production may not be good candidates for this
formulation.
o Patients who concurrently take anti cholinergic medication are not
suitable for oral dispersible tablets.
1.6  Challenges of Oral Dispersible Tablets 9, 10, 11
1.6.1  Fast Disintegration
ODTs should disintegrate in the mouth without the aid of water or with a
very small amount of water. The “fast disintegration” usually means disintegration
of tablets in less than 1 minute, but it is preferred to have disintegration as soon as
possible. The disintegration fluid is provided by the saliva of the patient.
1.6.2  Palatability
Oral dispersible tablets dissolve or disintegrate near the taste buds.
A pleasant taste inside the mouth becomes critical for patient acceptance. Unless the
drug is tasteless or does not have an undesirable taste, taste-masking techniques
should be used. An ideal taste-masking technique should provide good mouth feel
and should be compatible with ODT formulations. The amount of taste masking
material should be as low as possible to reduce the tablet size.
1.6.3  Tablet Strength and Porosity
In order to disintegrate the oral dispersible tablet in the oral cavity, the
tablet structure should have a highly porous network and should use low
compression force, which makes the tablets friable or brittle, which is difficult to
handle. Because the strength of a tablet is related to compression pressure, it is
important to find the porosity that allows fast water absorption while maintaining
high mechanical strength.
51.6.4  Hygroscopicity
             Generally oral dispersible tablets are hygroscopic and cannot maintain
physical integrity under normal conditions of temperature and humidity. This
problem can be especially challenging because many highly water soluble excipients
are used in the formulation to enhance fast dissolving properties as well as to create
good mouth feel. Those highly water soluble excipients are susceptible to moisture.
Hence they need protection from various environmental conditions.
1.6.5  Size of Tablet
              The degree of ease when taking a tablet depends on its size. It has been
reported that the easiest size of tablet to swallow is 7-8mm while the easiest size to
handle was one larger than 8mm. Therefore, the tablet size that is easy to take and
easy to handle is difficult to achieve.
1.6.6  Amount of Drug
              ODTs are limited by the amount of drug that can be incorporated into each
unit dose. For lyophilized dosage forms, the drug dose must be lower than 400mg
for insoluble drugs and less than 60mg for soluble drugs. This parameter is
particularly challenging when formulating a fast-dissolving oral films.
1.7 Techniques Used For the Formulation of Oral Dispersible Tablets
Many techniques have been reported
1.7.1  Freeze-Drying or Lyophilization 12, 13, 14:
Freeze drying is the process in which water is sublimed from the product
after it is frozen. This technique creates an amorphous porous structure that can
dissolve rapidly. The active drug is dissolved or dispersed in an aqueous solution of
a carrier/polymer and the mixture is dosed by weight and poured in the wells of the
bluster packs. The trays holding the blister packs are passed through liquid nitrogen
6freezing tunnel to freeze the drug solution or dispersion. Then the frozen blister
packs are placed in refrigerated cabinets to continue the freeze-drying. After freeze-
drying the aluminum foil backing is applied on a blister-sealing machine. Finally the
blisters are packaged and shipped. The freeze-drying technique has improved
absorption and increase in bioavailability.
Disadvantages:
* Expensive and time consuming
* Fragility makes conventional packaging unsuitable for these products
and poor stability under stressed conditions.
1.7.2 Tablet Molding 15, 16
Molding process is of two types
? Solvent method: Solvent method involves moistening the powder
blend with a hydro alcoholic solvent followed by compression at low
pressures in molded plates to form a wetted mass (compression
molding). The solvent is than removed by air-drying. The tablets
manufactured in this manner are less compact than the compressed
tablets and posses a porous structure that hastens dissolution.
? Heat method: Heat molding process involves preparation of a
suspension that contains a drug, agar and sugar (e.g. mannitol or
lactose) and pouring the suspension in the blister packaging wells,
solidifying the agar at the room temperature to form a jelly and
drying at 30?C under vacuum.
The mechanical strength of molded tablets is a matter of great concern.
Binding agents, which increase the mechanical strength of the tablets, need to be
incorporated. Taste masking is an added problem to this technology. The taste
masked drug particles were prepared by spray congealing, a molten mixture of
7hydrogenated cottonseed oil, sodium carbonate, lecithin, polyethylene glycol, and an
active ingredient, into a lactose based tablet triturate form. Compared to the
lyophillization technique, tablets produced by the molding technique are easier to
scale up for industrial manufacture.
1.7.3  Spray Drying 17, 18
In this technique, gelatin can be used as a supporting agent and as a matrix,
mannitol as a bulking agent and sodium starch glycolate or croscarmellose or
crospovidone are used as superdisintegrants. Tablets manufactured from the spray-
dried powder have been reported to disintegrate in less than 20 seconds in aqueous
medium. The formulation contained bulking agent like mannitol and lactose, a
superdisintegrant like sodium starch glycolate & croscarmellose sodium and acidic
ingredient (citric acid) and/or alkaline ingredients (e.g. sodium bicarbonate). This
spray-dried powder, which compressed into tablets showed rapid disintegration and
enhanced dissolution.
1.7.4  Sublimation 19, 20, 21
To generate a porous matrix, volatile ingredients are incorporated in the
formulation that is later subjected to a process of sublimation. Highly volatile
ingredients like ammonium bicarbonate, ammonium carbonate, benzoic acid,
camphor, naphthalene, urea, urethane and phthalic anhydride may be compressed
along with other excipients into a tablet. This volatile material is then removed by
sublimation leaving behind a highly porous matrix. Tablets manufactured by this
technique have reported to usually disintegrate in 10-20 sec. Even solvents like
cyclohexane, benzene can be used as pore forming agents.
8Drug + Volatizing agent + Other excipients
   Compression
? ? ? Volatizing agent
                                           Compressed tablet
Sublimation
                                                  °   °   ° Pores developed on sublimation
                                                                                 Of volatilizing agent
Fig 1: Steps involved in Sublimation
1.7.5 Direct Compression 22, 23
Direct compression represents the simplest and most cost effective tablet
manufacturing technique. This technique can now be applied for the preparation of
ODT because of the availability of improved excipients especially
superdisintegrants and sugar based excipients.
1.7.5.1  Superdisintegrants
In many orally disintegrating tablet technologies based on direct
compression, the addition of superdisintegrants principally affects the rate of
disintegration and hence the dissolution. The presence of other formulation
ingredients such as water-soluble excipients and effervescent agents further hastens
the process of disintegration.
91.7.5.2  Sugar Based Excipients
This is another approach to manufacture ODT by direct compression. The
use of sugar based excipients especially bulking agents like dextrose, fructose,
isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch hydrolysate,
polydextrose and xylitol, which display high aqueous solubility and sweetness, and
hence impart taste masking property and a pleasing mouthfeel. Mizumito et al have
classified sugar-based excipients into two types on the basis of molding and
dissolution rate.
Type 1 saccharides (lactose and mannitol) exhibit low mouldability but
high dissolution rate.
Type 2 saccharides (maltose and maltilol) exhibit high mouldability and
low dissolution rate.
1.7.6  Cotton Candy Process24
The cotton candy process is also known as the “candy floss” process and
forms on the basis of the technologies such as Flash Dose30 (Fuisz Technology). An
ODT is formed using a candyfloss or shear form matrix; the matrix is formed from
saccharides or polysaccharides processed into amorphous floss by a simultaneous
action of flash melting and centrifugal force. The matrix is then cured or partially
recrystallised to provide a compound with good flow properties and compressibility.
The candyfloss can then be milled and blended with active ingredients and other
excipients and subsequently compressed into ODT. However, the high processing
temperature limits the use of this technology to thermostable compounds only.
1.7.7  Mass-Extrusion 25, 26
This technology involves softening the active blend using the solvent
mixture of water-soluble polyethylene glycol and methanol and subsequent
expulsion of softened mass through the extruder or syringe to get a cylinder of the
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product into even segments using heated blade to form tablet. The dried cylinder can
also be used to coat granules for bitter drugs and thereby achieve taste masking.
1.8 Patented Technologies for Mouth Dissolving Tablets 27-31
? Zydis Technology.
? Durasolve Technology.
? Orasolve Technology.
? Flash Dose Technology.
? Wow Tab Technology.
? Flash Tab Technology.
? Oraquick Technology.
? Quick –Dis Technology.
? Nanocrystal Technology.
1.8.1  Zydis Technology
Zydis, the best known of the mouth-dissolving/disintegrating tablet
preparations, was the first marketed new technology tablet. A Zydis tablet is
produced by lyophilizing or freeze-drying the drug in a matrix usually consisting of
gelatin. The product is very lightweight and fragile, and must be dispensed in a
special blister pack. The Zydis product is made to dissolve on the tongue in 2 to 3
seconds. A major claim of the Zydis product is increased bioavailability compared
to traditional tablets. Because of its dispersion and dissolution in saliva while still in
the oral cavity, there can be a substantial amount of pre-gastric absorption from this
formulation. Any pre-gastric absorption avoids first-pass metabolism and can be an
advantage in drugs that undergo a great deal of hepatic metabolism. There are some
disadvantages to the Zydis technology. As mentioned earlier, the Zydis formulation
is very lightweight and fragile, and therefore should not be stored in backpacks or
the bottom of purses. Finally, the Zydis formulation has poor stability at higher
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temperatures and humidities. It readily absorbs water, and is very sensitive to
degradation at humidities greater than 65%. Example: loratidine
1.8.2 Orasolve Technology
OraSolve was Cima's first mouth-dissolving/disintegrating dosage form.
The  OraSolve  technology,  unlike  Zydis,  disperses  in  the  saliva  with  the  aid  of
almost imperceptible effervescence. The OraSolve technology is best described as a
mouth disintegrating tablet; the tablet matrix dissolves in less than one minute,
leaving coated drug powder. The major disadvantage of the OraSolve formulations
is its mechanical strength. The OraSolve tablet has the appearance of a traditional
compressed tablet. However, the OraSolve tablets are only lightly compressed,
yielding a weaker and more brittle tablet in comparison with conventional tablets.
An advantage that goes along with the low degree of compaction of OraSolve is that
the particle coating used for taste masking is not compromised by fracture during
processing. These formulations can accommodate single or multiple active
ingredients and tablets containing more that 1.0 g of drug have been developed.
Their disintegration time is less than 30 seconds. The OraSolve formulations are not
very hygroscopic. Example: zolmitriptan
1.8.3  Durasolve Technology
DuraSolve is Cima's second-generation mouth-dissolving/disintegrating
tablet formulation. Produced in a fashion similar to OraSolve, DuraSolve has much
higher mechanical strength than its predecessor due to the use of higher compaction
pressures during tableting. DuraSolve tablets are prepared by using conventional
tabletting equipment and have good rigidity (friability less than that 2%). The
DuraSolve product is thus produced in a mouther and more cost-effective manner.
DuraSolve is so durable that it can be packaged in traditional blister packaging,
pouches or vials. One disadvantage of DuraSolve is that the technology is not
compatible with larger doses of active ingredients, because the formulation is
subjected to such high pressures on compaction. Example: risperidone
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1.8.4  Flash Dose Technology
The Flash Dose technology utilizes a unique spinning mechanism to
produce a floss-like crystalline structure, much like cotton candy. This crystalline
sugar can then incorporate the active drug and be compressed into a tablet. This
procedure has been patented by Fuisz and is known as Shearform. The final product
has a very high surface area for dissolution. It disperses and dissolves quickly once
placed onto the tongue. Flash dose tablets consist of self–binding shearform matrix
termed as “floss”. Shearform matrices are prepared by flash heat processing and are
of two types. Example: ibuprofen
1.8.5  Wowtab Technology
The Wowtab mouth-dissolving/disintegrating tablet formulation has been
on the Japanese market for a number of years.  The WOW in Wowtab signifies the
tablet  is  to  be  given  “Without  Water”.  The  Wowtab  technology utilizes  sugar  and
sugar-like (e.g., mannitol) excipients. This process uses a combination of low
mouldability saccharides (rapid dissolution) and high mouldability saccharide (good
binding property).The two different types of saccharides are combined to obtain a
tablet formulation with adequate hardness and mouth dissolution rate. Due to its
significant hardness, the Wowtab formulation is a bit more stable to the environment
than the Zydis or OraSolve. It is suitable for both conventional bottle and blister
packaging. The Wowtab product dissolves quickly in 15 seconds or less. Example:
famotidine
1.8.6  Flashtab Technology
Prographarm laboratories have patented the Flashtab technology. This
technology involves the preparation of rapidly disintegrating tablet which consists of
an active ingredient in the form of microcystals. Drug microgranules may be
prepared by using the conventional techniques like coacervation, extrusion-
spheronization, simple pan coating methods and microencapsulation. The
microcrystals of microgranules of the active ingredient are added to the granulated
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mixture of excipients prepared by wet or dry granulation, and compressed into
tablets. All the processing utilized the conventional tabletting technology, and the
tablets produced are reported to have good mechanical strength and disintegration
time less than one minute. Example: ibuprofen
1.8.7  Oraquick Technology
The Oraquick mouth-dissolving/disintegrating tablet formulation utilizes a
patented taste masking technology. The taste masking process does not utilize
solvents of any kind, and therefore leads to mouther and more efficient production.
Also, lower heat of production than alternative mouth-dissolving/disintegrating
technologies makes Oraquick appropriate for heat-sensitive drugs. KV
Pharmaceutical claims that the matrix that surrounds and protects the drug powder in
microencapsulated particles is more pliable, meaning tablets can be compressed to
achieve significant mechanical strength without disrupting taste masking. Oraquick
claims quick dissolution in a matter of seconds, with good taste-masking. There are
no products using the Oraquick technology currently on the market, but KV
Pharmaceutical has products in development such as analgesics, scheduled drugs,
cough and cold, psychotropics, and anti-infectives. Example: hyoscyamine sulfate
1.8.8  Quick –Dis Technology
Lavipharm has invented an ideal intra-oral mouth dissolving drug delivery
system, which satisfies the unmet needs of the market. The novel intra-oral drug
delivery system, trademarked Quick-Di, is Lavipharm’s proprietary patented
technology and is a thin, flexible, and quick-dissolving film. The film is placed on
the top or the floor of the tongue. It is retained at the site of application and rapidly
releases the active agent for local and/or systemic absorption. The typical
disintegration time is only 5 to 10 seconds for the Quick-Di film with a thickness of
2 mm. The dissolving time is around 30 seconds for Quick Di film with a thickness
of 2 mm.
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1.8.9  Nanocrystal Technology
For mouth dissolving tablets, Elan's proprietary NanoCrystal technology
can enable formulation and improve compound activity and final product
characteristics. Decreasing particle size increases the surface area, which leads to an
increase in dissolution rate. This can be accomplished predictably and efficiently
using NanoCrystal technology. NanoCrystal particles are small particles of drug
substance, typically less than 1000 nm in diameter, which are produced by milling
the drug substance using a proprietary wet milling technique. NanoCrystal colloidal
dispersions of drug substance are combined with water-soluble ingredients, filled
into blisters, and lyophilized. The resultant wafers are remarkably robust, yet
dissolve in very small quantities of water in seconds. Example: rapamycin
1.9 Mechanism of Superdisintegrants 32, 33, 34
The tablet  breaks  to  primary  particles  by  one  or  more  of  the  mechanisms
listed below
1.9.1 Wetting
When disintegrants with exothermic properties gets wetted, localized stress
is generated due to capillary air expansion, which helps in disintegration of tablet.
This explanation, however, is limited to only a few types of disintegrants and cannot
describe the action of most modern disintegrating agents.
1.9.2 Swelling
Perhaps the most widely accepted general mechanism of action for tablet
disintegration is swelling. Tablets with high porosity show poor disintegration due to
lack of adequate swelling force. On the other hand, sufficient swelling force is
exerted in the tablet with low porosity. It is worthwhile to note that if the packing
fraction is very high, fluid is unable to penetrate in the tablet and disintegration is
again slows down.
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1.9.3 Porosity and capillary action (Wicking):
Disintegration by capillary action is always the first step. When we put the
tablet into suitable aqueous medium, the medium penetrates into the tablet and
replaces the air adsorbed on the particles, which weakens the intermolecular bond
and breaks the tablet into fine particles. Water uptake by tablet depends upon
hydrophilicity of the drug/excipient and on tableting conditions. For these types of
disintegrants maintenance of porous structure and low interfacial tension towards
aqueous fluid is necessary which helps in disintegration by creating a hydrophilic
network around the drug particles.
       Wicking   Swelling
Water is pulled into pores by Particles swell and break up
disintegrant and reduced the physical the matrix form within; swelling
bonding force between particles. Setup; localized stress spreads
         throughout the matrix.
Fig. 2: Disintegration of Tablet by Wicking and Swelling
1.9.4  Particle Repulsive Theory
Another mechanism of disintegration attempts to explain the swelling of
tablet made with ‘non-swellable’ disintegrates. Guyot-Hermann has proposed a
particle repulsion theory based on the observation that non-swelling particle also
cause disintegration of tablets. The electric repulsive forces between particles are the
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mechanism of disintegration and water is required for it. Researchers found that
repulsion is secondary to wicking.
1.9.5  Deformation
During tablet compression, disintegrated particles get deformed and these
deformed particles get into their normal structure when they come in contact with
aqueous media or water. Occasionally, the swelling capacity of starch was improved
when granules were extensively deformed during compression. This increase in size
of  the  deformed  particles  produces  a  breakup  of  the  tablet.  This  may  be  a
mechanism of starch and has only recently begun to be studied.
Deformation  Repulsion
Particles swell to pre compression                           Water is drawn into pores and
size and break up the matrix                                        particles repel each other
because of the resulting electrical force
Fig 3: Disintegration of Tablet by Deformation and Repulsion
1.9.6 Release of Gases
Carbon  dioxide  released  within  tablets  on  wetting  due  to  interaction
between bicarbonate and carbonate with citric acid or tartaric acid. The tablet
disintegrates due to generation of pressure within the tablet. This effervescent
mixture is used when pharmacist needs to formulate very rapidly dissolving tablets
or fast disintegrating tablet. As these disintegrants are highly sensitive to small
changes in humidity level and temperature, strict control of environment is required
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during manufacturing of the tablets. The effervescent blend is either added
immediately prior to compression or can be added in to two separate fraction of
formulation.
Table 1 List of Superdisintegrants35
Superdisintegrants Example Mechanism of
action
Special comment
Crosscarmellose®
Ac-Di-Sol®
Nymce ZSX®
Primellose®
Solutab®
 Vivasol®
L-HPC
Crosslinked
cellulose
-Swells 4-8
folds in < 10
seconds.
-Swelling and
wicking both.
-Swells in two
dimensions.
-Direct compression or
granulation
-Starch free
Crosspovidone
Crosspovidon M®
Kollidon®
Polyplasdone®
Crosslinked
PVP
-Swells very
little and returns
to original size
after
compression but
act by capillary
action
-Water insoluble and
spongy in nature so get
porous tablet
Sodium starch
glycolate
Explotab®
Primogel®
Crosslinked
starch
-Swells 7-12
folds in <
30 seconds
-Swells in three
dimensions and high
level serve as sustain
release matrix
Alginic acid NF
Satialgine®
Crosslinked
alginic acid
-Rapid swelling
in aqueous
medium or
wicking action
-Promote disintegration
in both dry or wet
granulation
Soy polysaccharides
Emcosoy®
Natural super
disintegrant
-Does not contain any
starch or sugar. Used in
nutritional products.
Calcium silicate -Wicking
action
-Highly porous,
-Light weight
-Optimum concentration
is between 20-40%
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Table 2  Commercially Available Mouth Dissolving Tablets36
Technologies Trade Name Active Ingredient Manufacturer
Feldene Fast Melt Piroxicam Pfizer, USA
Claritin Redi Tab Loratidine Schering plough, USA
Maxalt MLT Rizatriptan Merck, USA
Zyprexia Olanzepine Eli Lilly, USA
Pepcid RPD Famotidine Merck, USA
Zofran ODT Ondansetron Glaxo, UK
Zooming ZMT Zolmitriptan AstraZeneca, USA
Freeze Drying
Zelapar TM Selegilline Amarin,UK
Tempra Quicklets Acetaminophen Bristol Myers, USA
Febrectol Paracetamol Prographarma, France
Nimulid MDT Nimesulide Panacea Biotech, India
Torrox MT Rofecoxib Torrent pharma, India
Olanex Instab Olanzapine Ranbaxy, India
Disintegrant
Addition
Romilast Montelukast Ranbaxy, India
Sugar Based
Excipient
Benadryl Fastmelt
Diphenhydramine
& Pseudoephedrine
WarnerLambert, USA
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Literature Review
? Asija Rajesh et al., (2012)37 investigation was to mask the bitter taste
of tramadol hydrochloride and develop the orodispersible tablets and
study the effect of various factors on percent drug complexation. Ion
exchange resins like Kyron-114, Indion-234 and Tulsion-339 were
used in different ratios to mask the taste by forming the complex.
Superdisintegrants like Kyron-314 and crascarmellose sodium were
used in different concentrations and tablets were formulated by direct
compression.
? Mansing  G.  Patil et al., (2011)38 in their article reviewed taste
masking, formulation and evaluation of Tramadol hydrochloride. In
the present study an attempt has been made to prepare bitter less
orally disintegrating tablet of Tramadol hydrochloride using Eudragit
E100 as a taste masking agent. Superdisintegrants like crospovidone,
croscarmellose sodium and sodium starch glycolate were used, the
prepared blend was evaluated for pre-compressional parameters.
Tablets were compressed by Mass extrusion technique and evaluated.
Thus the study concludes, successful taste masking and tablets
contain crospovidone showed fastest disintegration.
? Ganure Ashok L et al., (2011)39 developed mouth dissolving tablets
of tramadol hydrochloride. The bitter taste of drug is prevented by
coating granules with isopropanol for specific duration after wet
granulation, the granules were then formulated with Aspartame,
MCC,  Sodium  croscarmellose  and  Sodium  starch  glycolate  and
compressed by direct compression technique. Different types of
evaluation parameters for the tablets were used. Evaluation of the
tablets showed that all the tablets were found to be within official
limits.
20
? Neeharika V et al.,(2011)40 designed  to  study  the  difference  in
disintegration time, wetting efficiency of poorly soluble levofloxacin
and freely soluble tramadol hydrochloride using natural and synthetic
superdisintegrant. The effect of natural superdisintegrants like
isolated mucilage of Plant ago ovate, Hibiscus rosa-sinensis and
synthetic superdisintegrants like croscarmellose sodium (Ac-Di-Sol)
were compared in different concentrations. The blend were evaluated
for pre-compression parameters and formulated by direct
compression technique. The tablets were evaluated and the
physicochemical parameters of dried powdered mucilage were
studied. The results showed that natural super disintegrants found to
have better disintegration property than the synthetic super
disintegrant. The comparative study of poorly soluble levofloxacin
and freely soluble tramadol hydrochloride did not show any
difference in disintegration time or wetting efficiency with natural or
synthetic disintegrants.
? Mahaveer Pr. Khinchi et al., (2011)41 developed the orally dispersible
tablets of Famotidine. Superdisintegrants like Ac-Di-Sol,
Crospovidone, Sodium starch glycolate and diluents like dibasic
calcium phosphate were used in the formulation of tablets. The
tablets were prepared by direct compression and were evaluated. In
this study maximum drug release and minimum disintegration time
were observed with crospovidone.
? Parikh Bhavik AnjanKumar et al., (2011)42 designed and evaluated
taste mask oral disintegration tablet of lornoxicam. Taste making is
done by complexation with ?-cyclodextrin by Kneading method.
Crospovidone was used as superdisintegrant and tablets were
formulated by sublimation technique and effervescent method. The
prepared tablets were evaluated. The results showed that the tablets
prepared by sublimation technique have more % of drug release than
that by effervescent method.
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? Ganga Srinivasan et al., (2011)43 worked in formulation development
and evaluation of tramadol hydrochloride orally disintegrating tablets
using galen IQ as a diluents. Superdisintegrants like Crospovidone,
Croscarmellose sodium, Sodium starch glycolate and Starch 1500.
Tablets were prepared by direct compression technique and
evaluated. This study suggest that galen IQ could be successfully
used as a diluent in the formulation of tramadol hydrochloride orally
disintegrating tablet.
? Nitesh J Patel et al., (2011)44 research  was  to  compare  the  effect  of
subliming agents on the oral dispersible property of cinnarizine
tablets. Compressed tablets prepared by using soluble material like
mannitol which has low porosity. Subliming agents like camphor,
menthol, ammonium bicarbonate or thymol were used in the
development of oral dispersible tablets by sublimation technique to
increase the porosity of the tablets. A high porosity was achieved.
? Sagar Shanti et al., (2011)45 sustained release implant of tramadol
were prepared by extrusion method using specially designed extruder
with biodegradable naturally occurring polymer chitosan. By varying
the concentration of polymer and crosslinking time, these implants
could be used for pain management such as carcinomas, post
operative surgery, osteoarthritis, by suitable modification
? Paul et al., (2011)46 studied  the  effects  of  disintegrants  in  different
concentration  on  the  release  profile  of  zidovudine  ODTs.  Differtent
superdisintegrants like crospovidone (PPXL), croscarmellose sodium
(Ac-Di-Sol), sodium starch glycolate were used in formulating the
tablets by direct compression method. Developed ODTs were studied
for their physicochemical properties. Ac-Di-Sol 6% possessed least
disintegration time and offered better dissolution profile
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? Prakash Goudanavar et al., (2011)47 develop the orodispersible tablet
of lamotrigine. Bitter taste of the drug is successfully masked by
forming inclusion complex with hydroxypropyl ?-cyclodextrin
employing Kneading method. The complex was compressed into
tablets along with superdisintegrants such as Kyron T-314, sodium
starch glycolate, Indion-414, croscarmellose sodium and
crospovidone  in  different  concentration.  HP?CD  is  also  useful  to
enhance the solubility. Orodispersible tablets were characterized by
Fourier Transformer Infrared Spectroscopy, Differential Scanning
Calorimetry and Powder X-Ray Diffraction Analysis. The prepared
tablets were evaluated. Formulation containing higher concentration
of Indion-414 decreases disintegration time and optimize the drug
release.
? Dayakar Rao Kalakuntla et al., (2011)48 develop  a  bitterless  oral
disintegrating tablet of Lornoxicam. Lornoxiam is a non steroidal
anti-inflammatory drug belongs to the class oxicams. Taste masking
is done by complexing Lornoxicam with Eudragit E100.
Superdisintegrants like sodium starch glycolate and Indion-414. The
tablets were evaluated.
? Sunitha S et al., (2011)49 determine the effect of solvents on
microencapsulation tramadol hydrochloride. Solvents like acetone,
dimethyldigol, 1,4-dioxan and non-solvents like n-hexane and
chloroform. The microspheres were prepared by following
coacervation phase separation using various non-aqueous solvents.
Microspheres were characterized for the particle size distribution,
wall thickness by scanning electron microscopy. The curve fitting
data revealed that the release followed first order kinetics.
? Mishra S.K et al., (2011)50 develop  once  daily  controlled  release
matrix tablets of Tramadol Hcl. Using different polymers like
Eudragit RS-100, Ethylcellulose, Carbopol 934P and Polyvinyl
Pyrolidone  controlled  release  matrix  tablets  of  tramadol  HCL  were
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formulated and evaluated. Different release models were applied to
in-vitro drug release data in order to evaluate the drug release
mechanisms and kinetics.
? Shankar Avulapati et al., (2010)51 this  study  was  to  incorporate  a
combination of superdisintegrants in optimum concentrations which
can  minimize  disintegration  time  of  losartan  potassium  ODTs.  The
various superdisintegrants used in the present study were sodium
starch glycolate, croscarmellose sodium, crospovidone. Tablets were
formulated by direct compression and evaluated for various
physicochemical parameters.
? Kumar  N et al., (2010)52 developed fast dissolving tablets of
granisetron hydrochloride. A combination of superdisintegrants like
sodium starch glycolate-crospovidone, sodium starch glycolate-
croscarmellose sodium and sodium starch glycolate-L-hydroxy
propyl cellulose were used along with mannitol to enhance mouth
feel. Tablets were prepared by direct compression technique and
evaluated. Among all formulations, the formulation using 4%w/w
sodium starch glycolate and 2%w/w of crospovidone was found to be
a promising formulation.
? Suhas M. Kakade et al., (2010)53 development of orally disintegrating
tablets of sertraline to achieve a better dissolution rate. Orally
disintegrating tablets which dissolve or disintegrate instantly on the
patient tounge or buccal mucosa it is suited for tablets undergoing
high first pass metabolism and is used for improving bioavailability.
Sertraline is practically slightly soluble in water and extensively
absorbed after oral administration, the absolute bioavailability is
approximately 44% due to hepatic metabolisim. Superdisintegrants
like crospovidone, croscarmellose sodium and sodium starch
glycolate were used in formulating tablets by direct compression
technique. The tablets prepared were evaluated. Thus the study states
that crospovidone showed maximum dissolution rate.
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? Sunil H. Makwana et al., (2010)54 research was to mask the intensely
bitter  taste  of  ondansetron  Hcl  and  to  formulate  a  orodispersible  of
the taste masked drug. Taste masking was done using Indion-204 by
solvent evaporation technique in different ratios. Drug-resin complex
were optimized by considering parameters such as optimization of
resin concentration, swelling time, stirring time, pH and temperature
on maximum loading. Resinate was evaluated for taste masking,
characterized by X-Ray diffraction and infra red spectrometer. Thus,
results conclusively demonstrated successful masking of taste and
rapid disintegration of the formulated tablets in the oral cavity.
? Suhas M. Kakade et al., (2010)55 design the mouth dissolving tablets
of losartan potassium with a view to enhance the patient compliance
and  provide  quick  onset  of  action.  Due  to  first  pass  metabolisim  of
losartan potassium it has low solubility. Mouth dissolving tablets
prepared by direct compression and using superdisintegrants like
Polyplasdone XL 10, Croscarmellose sodium and Explotab in
different concentration and evaluated for the pre-compression
parameters. The prepared batches of tablets were evaluated. Among
all  formulations  Polyplasdone  XL  10  was  considered  to  be  best
formulation.
? B. K. Sridhar et al., (2010)56 develop and evaluate inclusion complex
of isoxsuprine hydrochloride. Taste masking was done by forming
inclusion complex with ?-cyclodextrin using Kneading method.
Tablets were prepared using superdisintegrants like sodium starch
glycolate, Ac-Di-Sol, crospovidone by direct compression. The
tablets were evaluated. The formulation having Ac-Di-Sol 5%
showed complete release of drug.
? Vineet Bhardwaj et al., (2010)57 objective was to prepare the mouth
dissolving tablet of Amlodipine. Superdisintegrants such as Ac-Di-
Sol, sodium starch glycolate, Kollidon-CL using different
concentrations. Camphor was used as a sublimating agent. Tablets
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were prepared by direct compression using mannitol as bulking
agent. The compressed tablets are dried for 5 hours to allow
sublimation  of  camphor  to  increase  the  porosity  and  tablets  were
evaluated. Ac-Di-Sol showed least disintegrating time and fast
dissolution.
? S. K. Sheth et al., (2010)58 develop a taste masked oral disintegrating
tablet of poorly soluble lornoxicam. Taste masking is done by
complexation with ?-cyclodextrin. Various superdisintegrants like
sodium starch glycolate, crospovidone, croscarmellose sodium were
used in formulating by direct compression method. Prepared tablets
were evaluated for various properties and stability studies were
conducted as per ICH guidelines. In this study tablets showed
enhanced dissolution.
? Jaykar .B et al., (2010)59 develop orodispersible tablets of terbutaline
sulphate which is widely used as a bronchial asthma. Tablets were
compressed using ac-di-sol, sodium carboxy methyl cellulose, alginic
acid, chitosan and microcrystalline cellulose by direct compression
method. Prepared tablets were evaluated.
? N.Kanakadurga devi et al., (2010)60 develop the formulation for
montelukast sodium which overcomes problems such as difficulty in
swallowing, inconvenience in administration. Attempt has been made
to prepare fast disintegrating tablets of montelukast sodium in the
oral cavity. Superdisintegrants like polyplasdone XL 10, Ac-Di-Sol
and primojel were used. The pure drug and formulation blend was
evaluated for pre-compressional parameters.tablets were prepared by
direct compression method and evaluated. Polyplasdone XL 10 was
recommended as asuitable disintegrant for the preparation of direct
compression melt-in-mouth tablets.
? Metker Vishal et al., (2010)61 to develop mouth dissolving tablets of
lornoxicam. A novel superdisintegrant Kyron T-314(polacrillin
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potassium) and menthol as subliming agent were used in the
formulation by wet granulation technique. The present study showed
rapid absorption, improved bioavailability, effective therapy and
patient compliance.
? Vinayak S. Modi et al.,(2010)62 design and evaluate matrix controlled
release delivery system of a highly water-soluble analgesic, tramadol
hydrochloride using HPMC K 100 M and Xanthan Gum alone and in
combination as retarding polymers. Tablets were prepared by direct
compression and wet granulation using PVP K 30 as granulating
agent. HPMC and XG were used alone. Combinations were designed
by using 32 –  full  factorial  design.  The  wet  granulation  and  directly
compressed tablets showed good flow property and compressibility.
For a water soluble drug single polymer like HPMC K 100 M or
Xanthan gum could not retard the release for longer time. But the
combination of these polymers significantly retarded the release rate.
? Raval S.B et al.,(2009)63 reported bitter less mouth dissolving tablets
of Tramadol hydrochloride using ion-exchange resin Indion-294 as
taste masking agent. Ion exchange resinates and tasteless granules
were prepared with Indion-294 in the ratio 1:2. The mouth dissolving
tablets of both resinates and granules were prepared with different
superdisintegrants like Croscarmellose sodium, Crospovidone and
Indion-234 in different concentration. The blend was examined for
their flow properties and tablets were evaluated for physiochemical
properties. The study concluded that tablets prepared by addition of
superdisintegrant Indion 234 have less disintegration time, fast and
more release than those prepared by crospovidone.
? C.P.Jain et al., (2009)64 formulated and evaluated fast dissolving
tablets of valsartan. Sodium starch glycolate, crospovidone,
croscarmellose sodium are the superdisintegrants used. Tablets were
prepared by direct compression technique and evaluated for physico-
chemical properties. Effect of disintegrant on disintegration
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behaviour of tablet in artificial saliva was evaluated. The release of
valsartan from fast dissolving tablets was found to follow non-
Fickian diffusion kinetics. Crospovidone showed fastest
disintegration.
? Neena Bedi et al., (2009)65 develop the mouth dissolving tablets of
oxacarbazepine. In this study mouth dissolving tablets were prepared
using two different technologies, direct compression method and
solid dispersion technology. Tablets produced by direct compression
method contain cospovidone as a super disintegrant and aspartame as
a sweetener. Tablets produced by solid dispersion technique contain
polyvinylpyrrolidine K-30 and polyethylene glycol 6000 in different
ratios to increase its water solubility. The results compared for both
the technologies showed that the oxcarbazepine tablets prepared
using solid dispersion technology was found to have good
technological properties.
? Parmar R.B. et al., (2009)66 develop a formulation which overcomes
problems such as difficulty in swallowing, inconvenience in
administration. The present research work was to held to develop fast
dissolving tablet of domperidone. Superdisintegrants like sodium
starch glycolate used in formulation by direct compression method.
All formulations were evaluated.
? Amrit B. Karmarkar et al., (2008)67 research was to develop in situ
gelling, bioadhesive nasal inserts of tramadol hydrochloride by
lyophilisation of polymer gel solutions. The prepared nasal inserts are
a new dosage form having a sponge-like structure. The bioadhesion
potential was significantly dependent on the Carbopol 971P:
polycarbophil weigh ratio. Diffusion across the nasal mucosa shows a
matrix-type  profile  and  the  T50%  was  found  to  increase  as  the
concentration of polycarbophil increased.
.
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? Adamo Fini et al., (2008)68 developed ibuprofen orally disintegrating
tablets. To prevent the bitter taste, the drug was associated with
Phospholipon-80H, a saturated lecithin, by wet granulation. The
granules were then coated using different film forming agents like
Kollicoat SR 30, Kollidon-90F, Eudragit RD 100. Coated granules
were formulated with superdisintegrants like Kollidon CL or
Explotab and a mannitol- based diluents like Pearlitol SD 200.
Combined action of hydrophobic lecithin and the coating delay the
release of the drug from the tablets. It was thus possible to obtain
orally disintegrating tablets and a delayed release of ibuprofen.
? B. Mishra et al., (2006)69 present study was to formulate and evaluate
matrix tablets of tramadol hydrochloride to achieve sustained drug
release with reduced frequency of drug administration, side effects
and improved patient compliance. Matrix tablets of tramadol HCL
were prepared by direct compression technique, using polymers like
HPMC, guar gum, xanthan gum alone and in combination in different
proportions. The drug release characteristics from matrix tablets were
compared with commercial sustained release tablet of tramadol
hydrochloride. Matrix tablets having HPMC prolonged the rate and
extent of drug release maximally followed by xanthan gum and gaur
gum. Increasing percentage of sodium carbonate in core further
prolonged the rate and extent of drug release.
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Aim and Objective
 The aim of the present investigation was to develop the formulation of
Tramadol hydrochloride orally dispersible tablet using direct compression
technique.
The objective of the study to clarify the effect of different
superdisintegrants like Crospovidone (CP), Croscarmellose sodium (CCS), Sodium
starch glycolate (SSG) on disintegration and dissolution properties of the drug. The
developed formulation tested for all the pharmacoepial and non-pharmacoepial
evaluation as orally dispersible tablets.
              The optimized formulation also subjected for the stability study as per ICH
guidelines and in vivo drug release study.
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Drug Profile 70, 71, 72
? Tramadol HCl  (USP)
Structure of Tramadol
IUPAC NAME          : 2-(dimethylaminomethyl)-1-(3-methoxyphenyl)
cyclohexan-1-ol
Molecular formula : C16H25NO2
Molecular weight         : 263.3752 g/mol
Melting point                : 180.181 °C
Solubilit : soluble in water
pKa : 9.41
Indications : Indicated in moderate to severe pain in conditions such as
* Arthritis, osteoarthritis and rheumatoid arthritis
* Diabetic neuropathy, trigeminal neuralgia, postoperative neuralgia
* Pain in fractures, disc prolapse, burn, sciatica, dental pains
* Cancer pain
Dose: 50-100 mg every 4 to 6 hours to a maximum dose of 400 mg/day.
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Mechanism of Action
Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-
receptor agonists. Opiate receptors are coupled with G-protein receptors and
function as both positive and negative regulators of synaptic transmission via
G-proteins that activate effector proteins. As the effector system is adenylate cyclase
and cAMP located at the inner surface of the plasma membrane, opioids decrease
intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of
nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine
and noradrenaline is inhibited. The analgesic properties of Tramadol can be
attributed to norepinephrine and serotonin reuptake blockade in the CNS, which
inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity
for the OP3 receptor and preferentially inhibits serotonin uptake and enhances
serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake
by stimulating alpha (2)-adrenergic receptors.
Absorption
Racemic tramadol is rapidly and almost completely absorbed after oral
administration. The mean absolute bioavailability of a 100 mg oral dose is
approximately 75%.The mean peak plasma concentration of racemic tramadol and
M1 occurs at two and three hours, respectively, after administration in healthy
adults.
Toxicity                      : LD50=350mg/kg (orally in mice)
Protein binding : 20%
Half life                      : 4to 6hrs
Metabolism
Tramadol undergoes hepatic metabolism via the cytochrome P450 isozyme
CYP2D6, being O- and N-demethylated to five different metabolites. Of these,M1
(O-Desmethyltramadol) is the most significant since it has 200 times the ?-affinity
32
of (+)-tramadol, and furthermore has an elimination half-life of nine hours,
compared with six hours for tramadol itself. In the 6% of the population who have
slow CYP2D6 activity, there is therefore a slightly reduced analgesic effect. Phase II
hepatic metabolism renders the metabolites water-soluble and they are excreted by
the kidneys. Thus reduced doses may be used in renal and hepatic impairment.
Adverse Effects
The most commonly reported adverse drug reactions are nausea, vomiting,
sweating and constipation. Drowsiness is reported, although it is less of an issue
than for other opioids. Respiratory depression, a common side effect of most
opioids, is not clinically significant in normal doses. Tramadol can decrease the
seizure threshold. When combined with SSRIs, tricyclic antidepressents,or in
patients with epilepsy, the seizure threshold is further decreased. Seizures have been
reported in humans receiving excessive single oral doses (700 mg) or large
intravenous doses (300 mg).
? ?-Cyclodextrin 73
Synonyms : Beta-cyclodextrin, ßCD, BCD, ß-Schardinger dextrin,
cyclodextrin B, INS No. 459
Definition  : A non-reducing cyclic saccharide consisting of seven
alpha-1, 4-linked Dglucopyranosyl units manufactured by
the action of cyclodextrin transglycolase on hydrolysed
starch followed by purification of the ß-cyclodextrin;
purification is by preparation of a ß-cyclodextrin/solvent
inclusion compound followed by steam-stripping of the
solvent before final purification.
Chemical names        : Cycloheptaamylose
Chemical formula     :  (C6H10O5)7
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Structural Formula
Formula weight   : 1135.00
Description       : Virtually odourless, slightly sweet tasting white or
almost white crystalline solid
Functional uses : Encapsulation agent for food additives, flavouring and
vitamins
Solubility            : Sparingly soluble in water; freely soluble in hot water;
slightly soluble in ethanol.
34
Excipient Profile
? Crospovidone 74
Non proprietary Names
BP : Crospovidone
PhEur :   Crospovidonum
USPNF :   Crospovidone
Synonyms : Crosspovidonum ; crospopharm ; croslinked
povidone; polyplasdone XL ; polyvinyl
polypyrrolidine.
Chemical name     : 1 – ethenyl – 2 - pyrrolidine homopolymer.
Chemical Structure
Description
Crospovidone is a white to creamy-white, finely divided, free flowing,
practically tasteless, odourless or nearly odourless, hygroscopic powder.
Empirical Formula and Molecular Weight
(C6H9NO) n, > 1000000
USP32-NF27 describes crospovidone as a water-insoluble synthetic
crosslinked homopolymer of N-vinyl-2-pyrrolidinone.
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Applications in Pharmaceutical Formulation
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent
used at 2-5% concentration in tablets prepared by direct compression or wet and
dry-granulation methods. It is rapidly exhibits high capillary activity and
pronounced hydration capacity, with little tendency to form gels. Larger particles
provide a faster disintegration than smaller particles. Crospovidone can also be used
as a solubility enhancer. With the technique of co-evaporation, crospovidone can be
used to enhance the solubility of poorly soluble drugs.
Typical Properties
PH :  5.0 – 8.0
Density :  1.22 g/cm3
Moisture Content  : Maximum moisture sorption is approximately 60%.
Solubility : Practically insoluble in water and most common
organic solvents.
Incompatibilities
Crospovidone is compatible with most organic and inorganic pharmaceutical
ingredients. When exposed to a high water level, crospovidone may form molecular
adduct with some materials like sulfathiazole, sodium salicylate, salicylic acid,
Phenobarbital and tannin.
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? Croscarmellose sodium75
Non Proprietary Name
USPNF: Croscarmellose sodium.
Synonyms
Ac-Di-sol; cross-linked corboxy methylcellulose sodium; Primellose.
Structural Formula
Functional category    : Tablet and capsule disintegrant.
Chemical name           : Cellulose, carboxymethyl ether, sodium salt,
cross-linked.
Description :  Croscarmellose sodium occurs as an
odourless, white-coloured powder.
Molecular weight        : 90000-700000.
 PH                                 :   5.0-7.0.
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Solubility :  Insoluble in water. Although croscarmelose sodium rapidly swells
to 4-8 times of its original volume on contact with water.
Stability and Storage Condition
               Croscarmellose sodium is stable though it is hygroscopic material.
A model tablet formulation prepared by direct compression, with Croscarmellose
sodium as disintegrant, showed no significant difference in drug dissolution after
storage at 300C for 14 months.
Incompatibilities
The efficacy of disintegrants, such as Croscarmellose sodium, may be
slightly reduced in tablet formulations prepared by wet granulation or direct
compression process which contain which contain hygroscopic material such as
sorbitol.
Safety
Croscarmellose is mainly used as a disintegrant in oral pharmaceutical
formulations and is generally regarded as an essentially nontoxic and nonirritant
material. However, oral consumption of large amount of Croscarmellose sodium
may have a laxative effect although the quantities used in solid dosage formulations
are unlikely to cause such problems.
Applications  :     Disintegrant in capsule – 10-25%
       Disintegrant in tablets   – 0.5-5%
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? Sodium Starch Glycolate 76
Non proprietary Name
BP :  Sodium starch glycolate
USPNF :  Sodium starch glycolate.
Synonyms    : Explotab, Primogel.
Structural Formula
Functional category       :            Tablet and capsule disintegrant.
Chemical names             : Sodium carboxymethyl starch.
Description
Sodium starch glycolate is a white to off-white, odourless, tasteless, free
flowing powder. It consists of oval or spherical granules, 30-100 ?m in diameter
with some less spherical granules ranging from 10-35 ?m in diameter.
Solubility : Practically insoluble in water; sparingly soluble in ethanol
(95%). In water it swells upto 300 times its volume.
Stability and
Storage Conditions : It  is  a  stable  material.  It  should  be  stored  in  a  well  closed
container to protect from wide variations in humidity and
temperature that may cause cracking.
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Incompatibilities : Incompatible with ascorbic acid.
Safety : It is generally regarded as non-toxic and non-irritant
material. However, oral ingestion of large quantities may be
harmful.
Applications :  As  a  disintegrant  in  tablet  (wet  granulation  and  direct
compression) and capsule formulation in 2-8% concentration.
? Micro Crystalline Cellulose77
Non Proprietary Names
BP                :  Microcrystalline Cellulose
JP                 :  Microcrystalline Cellulose
PhEur           :  Cellulose, Microcrystalline
USP-NF        :  Microcrystalline Cellulose
Synonyms  : Avicel PH; Celex; Cellulose gel; hellulosum
microcristallinum; Celphere; Ceolus KG; crystalline
cellulose; E460; Emcocel; ethispheres .
Structural Formula
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Description : Microcrystalline cellulose is a purified partially
depolymerised cellulose that occurs as a white, odourless,
tasteless, crystalline powder composed of porous particles. It
is commercially available in different particle sizes and
moisture grades that have different properties and
applications.
Chemical Name : cellulose
Empirical Formula and Molecular Weight
(C6H10O5) n     36000
where  n=220
Functional Category : Adsorbent; suspending agent; tablet and capsule
diluents; tablet disintegrant.
Stability and Storage Conditions
Microcrystalline cellulose is a stable through hygroscopic material. The
bulk material should be stored in a well-closed container in a cool, dry place.
Incompatibilities : Microcrystalline cellulose is a incompatible with strong
oxidizing agents.
Applications
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a
binder/diluents in oral tablet and capsule formulations where it is used in both wet-
granulation  and  direct-compression  processes.  In  addition  to  its  use  as  a
binder/diluents, microcrystalline cellulose also has some lubricant and disintegrant
properties that make it useful in tableting.
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? Colloidal Silicone Dioxide (Aerosil) 78
Nonproprietary Names
BP :      Colloidal anhydrous silica
PhEur :      Silica colloidalis anhydrica
USPNF : Colloidal silicon dioxide
Synonyms  :  colloidal silica, fumed silica, light anhydrous
silicic acid, silicic anhydride and silicon
dioxide fumed
Chemical Name  : Silica
Molecular Weight    : 60.08
Structural Formula :   SiO2
Functional Category : Adsorbent, anticaking agent, emulsion
stabilizer, glident, suspending agent, tablet
disintegrant, thermal stabilizer, and viscosity-
increasing agent.
Applications in Pharmaceutical Formulation or Technology
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and
food products. Its small particle size and large specific surface area gives desirable
flow characteristics that are exploited to improve the flow properties of dry powders
in a number of processes such as tabletting.
Description
Colloidal silicon dioxide is submicroscopic fumed silica with a particle size
of  about  15  nm.  It  is  a  light,  loose,  bluish-white-colored,  odorless,  tasteless,  and
non-gritty amorphous powder.
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Stability and Storage Conditions
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of
water without liquefying. When used in aqueous systems at a pH 0–7.5, colloidal
silicon dioxide is effective in increasing the viscosity of a system. However, at a pH
greater than 7.5 the viscosity-increasing properties of colloidal silicon dioxide are
reduced; and at a pH greater than 10.7 this ability is lost entirely since the silicon
dioxide dissolves to form silicates. Colloidal silicon dioxide powder should be
stored in a well-closed container. Some grades of colloidal silicon dioxide have
hydrophobic surface treatments that greatly minimize their hygroscopicity.
? Aspartame 79
Non proprietary Names
BP :  Aspartame
PhEur :  Aspartame
USP-NF :  Aspartame
Synonyms : aspartamum; aspartyl-L-phenylalaninate.
Chemical Name :  N-L-?-Aspartyl-L- phenylalanine 1-methyl ester
Structural Formula
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Empirical Formula and Molecular Weight
C14H18N2O5     294.30
Description : Aspartame  occurs  as  an  off  white,  almost
odourless crystalline powder with an intensely
sweet taste.
Functional Category : Sweetening agent.
Applications in Pharmaceutical Technology
Aspartame is used as an intense sweetening agent in beverage products,
food products, and table-top sweeteners, in pharmaceutical preparations including
tablets, powder mixes, and vitamin preparations. It enhances flavour systems and
can be used to mask some unpleasant taste characteristics; the approximate
sweetening power is 180-200 times that of sucrose.
44
Plan of the Work
? Characterization of API
? To perform Pre-formulation studies
? To develop and optimize the formula for Tramadol Hydrochloride
ODT
? Evaluation of Tramadol HCl ODT
* Thickness
* Hardness
* Friability test
* Disintegration time test
* Dispersion time test
* Drug content uniformity
* Dissolution study
* Assay
* Accelerated stability testing
* Invivo studies
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6.1 Materials
Table 3  List of Materials used in the Study
Sl. No Materials Manufacturer/Suppliers
1 Tramadol HCl KAPL, Banglore
2 ? cyclodextrin
Roquette pharma,
Germany
3 Microcrystalline cellulose KAPL, Banglore
4 Crospovidone KAPL, Banglore
5 Croscarmellose sodium KAPL, Banglore
6 Sodium starch glycolate KAPL, Banglore
7 Aspartame KAPL, Banglore
8 Aerosol KAPL, Banglore
9 Magnesium stearate KAPL, Banglore
10 Talc KAPL, Banglore
11 Mint flavour KAPL, Banglore
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Table  4 List of equipments
Sl. No Materials Manufacturer/Supplier
1 Electronic weighing balance Mettler Toledo (Germany)
2 Compression Machine Smart press SRC12i (Germany)
3 Hardness and Thickness tester
INWEKA Hardness tester
(Germany)
4 Friabilator Electrolab, EF-1W (USA)
5 Dissolution Apparatus USP – Type II Electrolab ED-2 Type-II (USA)
6 FTIR Shimadzu FTIR-8400S (Japan)
7 Hot Air Oven
NEWTRONIC HTA
instrumentation (p) LTD (India)
8 UV Spectrometer Shimadzu UV-1601pc (Japan)
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6.2 Methods
6.2.1 Pharmaceutical Buffer solutions
6.2.1.1  0.1M Hydrochloric Acid (USP) 80
50 ml potassium chloride in a 200 ml volumetric flask, add 85 ml of 0.2M
Hydrochloric acid and then add water to volume.
6.2.1.2  Phosphate Buffer 81
Place 50ml of 1M KH2PO4 in a 200 ml volumetric flask and mix 3.6 ml of
0.2M NAOH and dilute to volume with water.and pH was adjusted to 3.5 with
ortho-phosphoric acid.
6.2.2 Pre-formulation Studies
It is one of the important prerequisite in development of any drug delivery
system. A pre-formulation study concentrates on those physicochemical properties
of the new compound that could affect drug performance and development of
efficacious dosage form. It is the first step in the rational development of the drug
formulation.
6.2.2.1  Melting Point
Melting point of Tramadol HCl was determined by capillary method. Fine
powder of Tramadol HCl was filled in glass capillary tube (previously sealed on one
end). The temperature at which the drug started melting was noted and recorded.
6.2.2.2  Assay
              Weigh 50mg of tramadol hydrochloride and transferred to a 100ml
volumetric flask; the volume was made-up with 0.1 N HCl and sonicated for 30 min
to break the complex. The samples were filtered through Whattman filter paper No.
41, diluted suitably and absorbance was measured at 272 nm.
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6.2.2.3  Preparation of Standard calibration curve of Tramadol Hydrochloride
I Stock solution: A weighed amount of the Tramadol hydrochloride (100mg) was
taken and dissolved in 50ml of 0.1N hydrochloric acid and the volume was made up
with 100ml of 0.1 HCl.
II Stock solution: From  the  I-stock  solution  10ml  was  withdrawn  and  diluted to
50ml with 0.1N HCl to get a concentration of 200µg/ml. From standard stock
solution-2 aliquots sample of 1ml, 2ml, 3ml, 4ml, 5ml and 6ml were pipetted into
10ml  volumetric  flasks.  The  volume was  made  up  with  0.1  N HCl  to  get  the  final
concentration of 20,40,60,80 and 100µg/ml respectively. The absorbance of each
concentration was measured at 272 nm. From standard stock solution-2 aliquots
sample  of  1ml,  2ml,  3ml,  4ml,  5ml  and  6ml  were  pipetted  into  10ml  volumetric
flasks.  The  volume was  made  up  with  0.1  N HCl  to  get  the  final  concentration  of
20,40,60,80 and 100µg/ml respectively. The absorbance of each concentration was
measured at 272 nm.
6.2.2.4  Compatibility Studies by FTIR
Compatibility with polymers was confirmed by carrying out I R studies.
The pure drug and its formulations along with excipients were subjected to IR
studies. In the present study, the potassium bromide disc (pellet) method was
employed.
6.2.3 Taste Masking
6.2.3.1  Inclusion Complex using ?-cyclodextrin by Kneading Technique 82, 83
A mixture of Tramadol HCl and ? cyclodextrin  was ground in a glass
container  and a minimum amount of water was added Add small quantity  and
triturated  for 15-30min to get the slurry and air dried at 400c for 24hrs, pulvirised
and passed through sieve no:100 and stored in a dessicator over fused cacl2.
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6.2.3.2  Estimation of Drug Content of Complex
An accurately weighed amount of Drug-inclusion complex (~100) was
transferred to a 50ml volumetric flask; the volume was made-up with 0.1 N HCl and
sonicated for 30 min to break the complex. The samples were filtered through
Whattman filter paper No. 41, diluted suitably and absorbance was measured at 272
nm.
6.2.4 Preparation of Tablets
Step 1:  Sifting of the drug and the excipients
Composition of tablets is mentioned in Table 5. All materials were passed
through sieve no. 40.
Step 2:  Disintegrant was divided into two equal parts by weight. Drug complex,
one part of Superdisintegrant and aspartame.
Step 3:  Mixing
The sifted step 1 materials were blended for 10mins.
Step 4: Sifting
Blended mass were sifted through 20/40 mesh screen. Ten percent of the
fines were added to the mass and then blended for 2 minutes.
Step 5:  Blending and Lubrication
A weighted quantity of Aerosil and remaining superdisintegrant were added
to the mass and blended for five minutes.
Step 6:  Compression
The granules of the drug were compressed in a 16 station rotary
compression machine using flat faced punches of 10mm diameter.
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Table 5  Composition of Oral Dispersible tablet of Tramadol HCl (All
quantities in mg)
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Drug complex 151.2 151.2 151.2 151.2 151.2 151.2 151.2 151.2 151.2
Micro crystalline
cellulose
116.3 110.3 104.3 116.3 110.3 104.3 116.3 110.3 104.3
Crospovidone 12 18 24 _ _ _ _ _ _
Croscarmellose _ _ _ 12 18 24 _ _ _
Sodium starch
glycolate
_ _ _ _ _ _ 12 18 24
Aspartame 6 6 6 6 6 6 6 6 6
Aerosil 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5
Talc 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5
Magnesium
stearate
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Mint flavour 3 3 3 3 3 3 3 3 3
Total weight of
the tablet
300 300 300 300 300 300 300 300 300
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6.2.5 Evaluation of Granules
6.2.5.1  Bulk Density (Db) 84, 85
It is a ratio of mass of powder to bulk volume. The bulk density depends on
particle size distribution, shape and cohesiveness of particles. Accurately weighed
quantity of powder was carefully poured in to graduate measuring cylinder through
large funnel and volume was measured, which is called initial bulk volume. It is
expressed in gm/ml and is given by
Db = M / V0
where,  M is the mass of powder.
V0 is the bulk volume of the powder.
6.2.5.2  Tapped Density (Dt) 86
Ten gram of powder was introduced into a clean, dry 100 ml measuring
cylinder. The cylinder was then tapped 100 times from a constant height and the
tapped volume was read. It is expressed in gm/ml and is given by,
Dt = M / Vt
where,  M is the mass of powder.
Vt is the tapped volume of the powder.
6.2.5.3  Flow Properties
Angle of repose, compressibility index and Hausner ratio were evaluated as
per methods described in USP 30-NF25.
6.2.5.3.1 Angle of Repose 86, 87
For determining angle of repose a funnel was mounted on a stand at a fixed
height and a fix weighed quantity of each blend was poured through the funnel. The
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height and the base diameter of the pile was noted and angle of repose was
calculated as
Angle of repose = tan-1 (height/ 0.5 base)
Table 6  Flow Properties Corresponding to Angle of Repose
Flow character Angle of repose (degrees)
Excellent 25-30
Good 31-35
Fair-aid not needed 36-40
Passable-may hang up 41-45
Poor 46-55
Very poor 56-65
Very, very poor >66
6.2.5.3.2 Compressibility Index and Hausner’s Ratio84
In the recent years compressibility index and the closely related Hausner
ratio have become the simple, fast and popular methods of predicting powder flow
characteristics. The basic procedure to calculate the compressibility index and
Hausner ratio involves measuring the bulk volume (V0) and final tapped volume
(Vf). A 250 ml volumetric cylinder with 100 gm of the material is used for this
purpose. The calculations are done as:
Compressibility index = 100 (Vf- V0 )/ Vf
Hausner ratio = (Vf )/ V0
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Table 7  Flow Properties Corresponding to Compressibility Index and Hausner
Ratio
Flow character Compressibility index (%) Hausner ratio
Excellent <10 1.00-1.11
Good 11-15 1.12-1.18
Fair 16-20 1.19-1.25
Passable 21-25 1.26-1.34
Poor 26-31 1.35-1.45
Very poor 32-37 1.46-1.59
Very, very poor >38 >1.60
6.2.6 Evaluation of Oral Dispersible Tablets
6.2.6.1  General Appearance and Organoleptic Properties
The control of a general appearance of a tablet involves the measurement of
a number of attributes such as a tablet’s size, shape, color, presence or absence of an
odor, taste, surface texture, physical flaws and consistency, and legibility of any
identifying markings.
6.2.6.2  Shape, Thickness and Dimension85
Six tablets from each batch were selected and measured for thickness and
diameter  using  digital  vernier  calipers.  The  extent  to  which  the  thickness  of  each
tablet deviated from ± 5% of the standard value was determined.
54
6.2.6.3  Hardness
Five tablets from each batch were selected and hardness was measured
using Monsanto hardness tester to find the average tablet hardness.
6.2.6.4  Friability (%F) 85
20 tablets from each batch were selected randomly and weighed. These
tablets were subjected to friability testing using Roche friabilator for 100
revolutions. Tablets were removed, de-dusted and weighed again. Following
formula was used to calculate the % friability
%F =1-(loss in weight/ initial weight) 100
6.2.6.5  Weight Variation88
Weight variation was calculated as per method descried in Indian
Pharmacopoeia (I.P. 1996). 20 tablets were weighed individually and the average
weight was calculated. The requirements are met if the weights of not more than 2
tablets differ by more than the percentage listed in Table and no tablets differ in
weight by more than double that percentage.
                 Table 8 Weight Variations Allowed as per I.P. 1996
Average weight of tablet (mg) Percentage difference allowed
80 mg or less 10
More than 80 mg but less that 250 mg 7.5
250 mg or more 5
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6.2.6.6  Drug Content
Finely powder not fewer than 20 tablets. Transfer a portion of the powder,
equivalent to 50mg of tramadol hydrochloride, and transferred to a 100ml
volumetric flask; the volume was made-up with 0.1 N HCl and sonicated for 30 min
to break the complex. The samples were filtered through Whattman filter
paper No. 41, diluted suitably and absorbance was measured at 272 nm.
6.2.6.7  Disintegration Time88
The in-vitro disintegration time was determined by using disintegration test
apparatus. One tablet was placed in each of the six tubes of the apparatus and one
disc was added to each tube. The time in seconds taken for complete disintegration
of the tablet with no palpable mass in the apparatus was measured in seconds.
6.2.6.8  Wetting Time
A Petri dish containing 6 ml of distilled water was used. A tissue paper
folded twice was kept in the dish and a tablet was placed on it. A small quantity of
amaranth red color was put on the upper surface of the tablet. Time required for the
upper surface of the tablet to become red was noted as the wetting time of the tablet.
6.2.6.9  Dissolution Studies
The In vitro dissolution test was carried out using USP Type II dissolution
test apparatus at 37±2°C and 50 rpm speed. 900 ml of 0.1 N HCl was used as
dissolution medium. Aliquot equal to 10 ml was withdrawn at specific time intervals
and amount of Tramadol released from tablet was determined.
6.2.7 Release Kinetics
The results of In-vitro release profile obtained for all the formulations were
plotted in modes of data treatment as follows.
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1. Log cumulative percent drug remaining versus time (first order
kinetic model)
2.  Cumulative percent drug release versus square root of time (Higuchis
model)
3.  Cumulative percent drug release versus time (zero order kinetic
model)
 4. Log cumulative Percent Drug released versus log time
(korsmeyers model)
6.2.7.1 Drug Release Kinetics-model Fitting of the Dissolution Data 89 -91
Whenever a new solid dosage form is developed or produces, it is
necessary to ensure that drug dissolution occurs in an appropriate manner. Drug
dissolution from solid dosage forms has been described by kinetic models in which
the dissolved amount of drug (Q) is a function of the test time, t or Q = f (t). Some
analytical definitions of  the  Q (t)  function  are  commonly  used  such  as  zero  order,
first order, Higuchi, korsmeyers-peppas models. Other release parameters, such as
dissolution  time  (tx%),  dissolution  efficacy  (ED),  difference  factor  (f1), similarity
factor (f2) can be used to characterize drug dissolution / release profile.
1. Zero-order Kinetics
A zero-order release would be predicted by the following equation.
               At    =   Ao - Kot (1)
where,
At    =    Drug release at time t
Ao   =     Initial drug concentration
Ko   =     Zero-order rate constant (hr)
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When the data is plotted as cumulative percent drug release versus time if
the plot is linear then the data obeys zero-order release kinetics, with a slope equal to
ko.
Use:   This relation can be used to describe the drug dissolution of several types
of modified release pharmaceutical dosage forms, as in case of some
transdermal systems etc. the pharmaceutical dosage forms following this
profile release the same amount of drug by unit  of time and it  is  the ideal
method of drug release in order to achieve a prolonged pharmacological
action.
2. First-order Kinetics
A first order release would be predicted by the following equation.
Log C    =      Log Co - Kt / 2.303            (2)
where
C     =   Amount of drug remained at time t
Co  =   Initial amount of drug
K     =    First-order rate constant
When the data is plotted as log cumulative percent drug remaining versus
time yields a straight line indicating the release follows first-order kinetics, the
constant k can be obtained by multiplying 2.303 with slope values
Use: The pharmaceutical dosage forms containing water-soluble drugs in porous
matrices, follows this type of dissolution profile. The release of the drug is
proportional to the amount of drug remaining in its interior so that the
amount of drug release by unit of time diminishes
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3. Higuchi Model
Drug release from the matrix devices by diffusion has been described by
following higuchis classical diffusion equation.
Q = [DE/ ?(2A- ECs) Cst ]            (3)
where
Q    =    Amount of drug release at time t
D    =    Diffusion coefficient of the drug in the matrix
A     =    Total amount of drug in unit volume of matrix
Cs    =    The solubility of the drug in the matrix
E     =  Porosity of the matrix
T      =    Time in hrs at which q is the amount of drug is release
Equation-3 may be simplified if one assumes that D, Cs and A are
constant.  Then equation-3 becomes
Q    =    K t ½
When the data is plotted according to equation-4 i.e. cumulative drug
release versus Square root of time yields a straight line, indicating that the drug was
released by diffusion mechanism. The slope is equal to k.
Use: The relation can be used to describe the drug dissolution from several types
of modified release pharmaceutical dosage forms, as in case of some water
soluble drugs.
4. Korse Meyer Peppas Model
In order to understand the mode of release of drug from swellable matrices,
the data were fitted to the following equation
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Mt /    M? = Ktn
where,
Mt / M? = the fraction of drug released at time‘t’
K = Constant incorporating the structural and geometrical
                                  Characteristics of the drug / polymer system.
n = Diffusion exponent related to the mechanism of release.
The above equation can be simplified by applying log on both sides we get
Log       Mt /   M?    =     Log K+ n Log t
When the data is plotted as a log of drug released versus log time, yields a
straight line with a slope equal to n and the k can be obtained from y- intercept.
The value of n for a cylinder is <0.45 for fickian release,  > 0.45 and < 0.89
for non-fickian release, 0.89 for the case 2 release and > 0.89 for  super case2 type
release.
6.2.8 Stability Studies
The purpose of stability testing is to provide evidence on how the quality of
a drug substance or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light, and enables
recommended storage conditions and shelf lives to be established.
              In  the  present  study,  the  stability  studies  were  carried  out  as  per  ICH
guidelines 400C ± 20C / 75% ± 5% RH for the following selected formulation for 1
month.
Formulation F3
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After specified time intervals, parameters like physical appearance,
disintegration time, drug content, and dissolution were evaluated according to the
procedure described as earlier.
6.2.9 In vivo Studies 92, 93
Animals:  Healthy adult rabbits. (Approval number: IAEC/XXXIV/05/CLB
MCP/2011 dated 07.12.2011)
Procedure:  Physical examinations and plasma biochemical analyses were
performed to ensure rabbits were healthy prior to the experiment.
One blood sample was collected before treatment with tramadol
through marginal ear vein. Then, tramadol was administered once,
and blood samples were collected at various time points up to 6hrs
after administration. Blood samples were analyzed with high-
performance liquid chromatography to determine plasma
concentrations of tramadol.
Preparation of mobile phase, stock solution and plasma extraction method
for HPLC analysis:
The mobile phase comprises of phosphate buffer (potassium dihydrogen
phosphate 50mM) and its pH was adjusted to 3.5 using ortho-phosphoric acid. Then
methanol and acetonitrile were added to the buffer solution containing 0.1% triethly
amine. The mobile phase was sonicated and filtered through vacuum filter assembly
by using cellulose acetate filter (0.45_m). A stock solution was prepared by
dissolving 100mg of Tramadol hydrochloride in 100mLof methanol. Working
solutions were prepared in methanol by appropriate dilutions of stock solution. All
the solutions were stored at?200c and protected from light.
To 0.5mL of plasma, 500 ng of Tramadol hydrochloride (dissolved in
0.5mL distilled water) was added and vortexed for 2min. Methanol (2 mL) was
added to the plasma to precipitate plasma proteins and again vortexed for 1 min. The
final solution was subjected to centrifugation at 45,000rpm for 10 min. The
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supernatant liquid was filtered and transferred to epindroff tube for injecting in
HPLC port. Chromatographic separation was performed at ambient temperature on
ODS hypersil C18 stainless steel analytical column, 5?m pore size, 4.6mm×250mm
and Guard Column.
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Results
Table 9  Raw Material Analysis of Tramadol Hydrochloride
S. No Test Observation
1 Melting point 1830C
2 Solubility Water, Methanol
3 Assay 99.72%
Determination of Drug Content
When Drug complex was prepared using all of the optimized parameters
for drug loading, the percent drug loading was found to be 99.20% and hence the
drug content was 49.60% w/w.
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Fig. 4  FTIR Spectrum of Tramadol HCl
Fig. 5  FTIR Spectrum of ?-cyclodextrin
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Fig. 6  FTIR Spectrum of Drug Complex
Fig. 7  FTIR Spectrum of Drug Complex with MCC
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Fig. 8  FTIR Spectrum of Drug Complex with Crospovidone
Fig. 9  FTIR Spectrum of Drug Complex with Cros Carmellose Sodium
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Fig. 10  FTIR Spectrum of Drug Complex with SSG
Fig. 11  FTIR Spectrum of Drug Complex with Aerosil
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Fig. 12  FTIR Spectrum of Drug Complex with Magnesium Stearate
Fig.13  FTIR Spectrum of Drug Complex with Aspartame
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Fig.14  FTIR Spectrum of Drug Complex with Talc
Fig.15  FTIR Spectrum of Drug Complex with flavour
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Table 10 Standard calibration curve of Tramadol Hydrochloride using pH 1.2
Buffer (0.1M HCl)
S.No
Concentration
(µg/ml)
Absorbance
(nm)
1 0 0.000
2 20 0.126
3 40 0.262
4 60 0.366
5 80 0.484
6 100 0.611
Fig. 16  Standard Calibration Curve of Tramadol Hydrochloride using pH 1.2
Buffer (0.1M HCl)
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Table 11 Evaluation of precompressed granules of Tramadol HCl
Formulation
Bulk
density
(gm/cc)
±SD
Tapped
density
(gm/cc) ±SD
Compressibility
index (%) ±SD
Hausner’s
ratio
(%)±SD
Angle of
repose(?)
±SD
F1 0.289±0.023 0.344±0.03 13.47±0.002 1.155±0.04 21.98±0.03
F2 0.309±0.021 0.348±0.012 11.02±0.03 1.126±0.01 20.43±0.04
F3 0.296±0.012 0.321±0.02 7.78±0.001 1.084±0.03 19.69±0.02
F4 0.293±0.023 0.316±0.023 7.27±0.012 1.078±0.01 20.79±0.05
F5 0.312±0.032 0.375±0.012 16.80±0.023 1.201±0.02 22.31±0.04
F6 0.295±0.014 0.342±0.021 13.74±0.023 1.159±0.31 21.01±0.21
F7 0.307±0.032 0.370±0.021 17.02±0.001 1.205±0.01 22.24±0.04
F8 0.281±0.041 0.324±0.012 13.27±0.001 1.153±0.02 19.76±0.03
F9 0.318±.021 0.347±0.024 8.35±0.002 1.091±0.03 21.47±0.05
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Table 12 Evaluation of Compressed Granules of Tramadol Hydrochloride
Formulation Weight Variation Hardness
(kg/cm2)
Thickness (mm) Friability
(%)
F1 299±0.14 3.48±0.12 3.62± 0.016 0.462
F2 305±0.25 5.65±0.11 3.14±0.012 0.501
F3 301±0.01 4.53±0.14 3.42±0.01 0.442
F4 305±0.43 3.51±0.12 4.14±0.14 0.364
F5 304±0.38 4.21±0.14 3.27±0.03 0.409
F6 302±0.24 4.04±0.15 4.01±0.02 0.486
F7 298±0.18 4.79±0.14 3.93±0.12 0.423
F8 304±0.16 4.23±0.16 3.76±0.01 0.412
F9 306±0.41 4.54±0.13 4.15±0.13 0.389
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Table 13 Evaluation of Compressed Granules of Tramadol Hydrochloride
Formulation Wetting Time (sec)
Disintegrating
Time (sec)
Drug content
(%)
F1 75 31 98.23
F2 41 24 98.76
F3 23 18 99.12
F4 29 20 101.76
F5 30 27 100.14
F6 35 29 98.99
F7 29 32 99.01
F8 31 27 98.66
F9 27 26 98.41
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Table 14  Invitro Dissolution Profile of Tramadol HCl from ODTs (F1)
S.No Time (min) cumulative % drugrelease ± SD
1 5 63.87±0.48
2 10 71.12±0.32
3 15 82.93±0.56
4 20 91.47±0.21
5 30 98.88±0.18
All values are expressed as mean ± SD, n=3
Fig. 17 Invitro Dissolution Profile of Tramadol HCl from ODTs (F1)
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Table 15 Invitro Dissolution Profile of Tramadol HCl from ODTs (F2)
S.No Time (min) cumulative % drugrelease ± SD
1 5 67.31±0.42
2 10 74.02±0.12
3 15 82.35±0.41
4 20 90.20±0.23
5 30 97.15±0.32
All values are expressed as mean ± SD, n=3
Fig. 18 Invitro Dissolution Profile of Tramadol HCl from ODTs (F2)
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Table 16 Invitro Dissolution Profile of Tramadol HCl from ODTs (F3)
S.No Time (min) cumulative % drugrelease ± SD
1 5 61.05±0.16
2 10 69.66±0.12
3 15 78.11±0.32
4 20 90.29±0.21
5 30 99.18±0.18
All values are expressed as mean ± SD, n=3
Fig. 19 Invitro dissolution profile of Tramadol HCl from ODTs (F3)
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Table 17 Invitro dissolution profile of Tramadol HCl from ODTs (F4)
S.No Time (min)
cumulative % drug
release ± SD
1 5 65.81±0.32
2 10 74.42±0.12
3 15 82.32±0.16
4 20 89.38±0.21
5 30 94.87±0.18
All values are expressed as mean ± SD, n=3
Fig. 20 Invitro Dissolution Profile of Tramadol HCl from ODTs (F4)
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Table 18 Invitro Dissolution Profile of Tramadol HCl from ODTs (F5)
S.No Time (min)
cumulative % drug
release ± SD
1 5 59.11±0.21
2 10 67.15±0.16
3 15 76.10±0.23
4 20 87.21±0.12
5 30 96.74±0.34
All values are expressed as mean ± SD, n=3
Fig. 21 Invitro Dissolution Profile of Tramadol HCl from ODTs (F5)
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Table 19 Invitro Dissolution Profile of Tramadol HCl from ODTs (F6)
S.No Time (min)
cumulative % drug
release ± SD
1 5 67.89±0.16
2 10 74.92±0.32
3 15 85.83±0.21
4 20 90.58±0.23
5 30 97.54±0.14
All values are expressed as mean ± SD, n=3
Fig. 22 Invitro Dissolution Profile of Tramadol HCl from ODTs (F6)
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Table 20 Invitro Dissolution Profile of Tramadol HCl from ODTs (F7)
S.No Time (min)
cumulative % drug
release ± SD
1 5 68.71±0.16
2 10 75.45±0.25
3 15 81.06±0.13
4 20 92.84±0.21
5 30 98.42±0.33
All values are expressed as mean ± SD, n=3
Fig. 23 Invitro Dissolution Profile of Tramadol HCl from ODTs (F7)
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Table 21 Invitro Dissolution Profile of Tramadol HCl from ODTs (F8)
S.No Time (min)
cumulative % drug
release ± SD
1 5 72.49±0.23
2 10 81.62±0.21
3 15 88.51±0.33
4 20 94.96±0.14
5 30 97.21±0.17
All values are expressed as mean ± SD, n=3
Fig. 24 Invitro Dissolution Profile of Tramadol HCl from ODTs (F8)
81
Table 22 Invitro Dissolution Profile of Tramadol HCl from ODTs (F9)
S.No Time (min) cumulative % drugrelease ± SD
1 5 69.11±0.42
2 10 77.83±0.32
3 15 84.83±0.21
4 20 91.59±0.17
5 30 97.86±0.25
All values are expressed as mean ± SD, n=3
Fig. 25 Invitro Dissolution Profile of Tramadol HCl from ODTs (F9)
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Determination of Release Kinetics:
Table 23 Kinetic Studies of Oral Dispersible Tablets
Release kinetics R2 Intercept Slope
Zero order 0.971 54.48 1.573
First order 0.908 2.142 0.067
Higuchi 0.982 32.33 12.31
Korsmeyer peppas 0.972 1.577 0.280
Dissolution- Zero Order Kinetics
Fig. 26 Graph for the Formulation F3-Zero Order Kinetics
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Dissolution- First Order Kinetics
Fig. 27 Graph for the Formulation F3-First Order Kinetics
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Fig. 28 Graph for the Formulation F3-Higuchi model
Fig. 29 Graph for the Formulation F3- Korse Meyer Peppas model
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Stability Studies
Table 24  Stability Studies for F3 Formulation of Tramadol Hydrochloride
ODT at 40º C /75 % RH
Batch number and
stability condition Assay (%)
Dissolution study in pH
1.2 buffer
40º C/75 % RH
( Initial )
99.12% 99.18±0.16%
40º C/75 % RH
( 15 days )
99.64% 99.14±0.32%
40º C/75 % RH
( 1 month )
99.64% 99.76±0.12%
All values are expressed as mean ± SD, n=3
Table 25  Stability Studies for F3 Formulation of Tramadol Hydrochloride
ODT at 40º C /75 % RH
Batch number
and stability
condition
Friability (%) Hardness( kg/cm2 )
Disintegration
time (sec)
40º C/75 % RH
( Initial )
0.442 4.53±0.14 18
40º C/75 % RH
( 15 days )
0.482 4.49±0.10 18
40º C/75 % RH
( 1 month )
0.469 4.55±0.12 19
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Fig. 30 in vivo Calibration Curve in Plasma
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Table 26 invivo Pharmacokinetic Parameters for Marketed Formulation
Time (hr) Area (%) Concentration (ng/ml)
0 0 0
1 95.36 122.13
2 355.67 414.58
4 86.45 112.72
6 26.45 44.71
Fig. 31 invivo Pharmacokinetic Parameters for Marketed Formulation
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Table 27 Pharmacokinetic Parameters of Marketed Product
Cmax 414.6
Tmax 2.0
AUC( 0-t) 1014.2 ng-hr/ml
AUC( ? ) 1110.8 ng-hr/ml
AUMC??) 3325.1 ng-hr*hr/ml
E Phase 716.463
D/A Phase 830.576
MRT (area) 3.0 hr
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Table: 28 invivo Pharmacokinetic Parameters for Tramadol Hydrochloride (F3)
Time (hr) Area (%) Concentration (ng/ml)
0 0 0
1 81.42 98.42
2 289.58 371.51
4 61.35 85.83
6 19.16 30.16
Fig: 32 invivo pharmacokinetic parameters for Tramadol hydrochloride (F3)
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Table 29 Pharamacokinetic parameters of Tramadol hydrochloride (F3)
Cmax 371.5
Tmax 2.0
AUC( 0-t) 857.5 ng-hr/ml
AUC( ? ) 915.2 ng-hr/ml
AUMC??) 2536.8 ng-hr*hr/ml
E Phase 695.112
D/A Phase 772.892
MRT (area) 2.8 hr
91
7. Discussion
7.1 Raw Material Analysis of Tramadol Hydrochloride
               The experimental work started with raw material analysis of Tramadol
hydrochloride. Parameters of Tramadol HCl given in the I.P were in compliance and
reported in the Table 9.
7.2 Compatibility Study with Excipients
Fig 4 shows the FTIR spectra of plain Tramadol Hydrochloride
           IR  spectra  of  pure  Tramadol  HCL  showed  bands  at  3000  for  aliphatic  C-H
stretch, 2930 for CH2 absorptions, for isopropyl group shows bands near 1170 and
1145.
             IR spectra of drug and excipients physical mixture shown in Fig 5-15 also
revealed that no considerable change was observed in bands of Tramadol HCl;
hence it indicates the absence of interaction between the drug and excipients used in
the tablet.
7.3 Standard Calibration Curve for Tramadol Hydrochloride
The calibration curve of Tramadol hydrochloride in 0.1M HCl was derived
from the concentration and corresponding absorbance values. Linear regression
analysis gave the equation for the line of best fit as Y=0.006X+0.005. Linearity was
observed in the concentration range between 20 to 100?g/ml. The values were
shown in Table 10 and Fig 16.
7.4 Formulation Development
Tramadol hydrochloride is opoid analgesic; attempts have been made to
develop the oral dispersible tablets. The superdisintegrants used were Crospovidone,
Croscarmellose sodium and SSG used as disintegrating agents which decreases the
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disintegrating time and the effect of superdisintegrants on the drug release was
studied.
7.5 Preparation of Oral Dispersible Tablets
Tramadol Oral Dispersible Tablets were prepared using different
percentages of Crospovidone, Croscarmellose sodium and SSG as superdisintegrants
by direct-compression method.
The granules prepared using Crosspovidone for compression of orally
disintegrating tablets was evaluated. Angle of repose was in the range of 19.69±0.02
to 21.98±0.03. Bulk density & Tapped density has 0.289±0.023 to 0.309±0.0210 &
321±0.012 to 0.348±0.02. Compressibility index & Hausner’s ratio was found to
have in limit of 7.78±0.001 to 13.47±0.002 & 1.084±0.032 to 1.155±0.04. These
values indicate that the prepared granules exhibited good flow properties. The
results were shown in Table 11.
The granules prepared by using Crospovidone were compressed to tablets
and tablets are tested for its physical characteristics. The thickness of the tablets was
in the range of 3.14±0.012 to 3.62±0.016. The friability has 0.442 to 0.501. The
hardness & weight variation is in between 3.48±0.12 to 5.65±0.11 & 299±0.14 to
305±0.25. The wetting time & Disintegration time showed the values in the range of
23 to 75 & 18 to 31. The drug content varied in between 98.23 to 99.12. The results
are shown in Table 12-13.
               The granules prepared using Crosscarmellose sodium for compression of
orally disintegrating tablets was evaluated. Angle of repose was in the range of
20.79±0.05 to 22.31±0.001. Bulk density & Tapped density was found to have in the
range of 0.293±0.023 to 0.312±0.032 & 0.316±0.023 to 0.375±0.012.
Compressibility index & Hausner’s ratio lie in between 7.27±0.012 to 13.74±0.023
& 1.078±0.012 to 1.159±0.0041. These values indicate that the prepared granules
exhibited good flow properties. The results were shown in
Table 11.
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The granules prepared by using Croscarmellose sodium were compressed
to tablets and tablets are tested for its physical characteristics. The thickness of the
tablets was in between 3.27±0.03 to 4.14±0.14. The friability & hardness of the
tablets was 0.364 to 0.486 & 3.51±0.12 to 4.53±0.14. The weight variation of the
tablets lies in the range 302±0.24 to 305±0.43. The wetting time of the tablets was in
the range of 29 to 35. Disintegrating time of the tablets was in the range of 20 to 29.
The drug content varied in between 98.99 to 101.76. The results are shown in Table
12-13.
The granules prepared using Sodium starch glycolate for compression of
orally disintegrating tablets were evaluated. Angle of repose was in the range of
19.76±0.03 to 22.24±0.04. Bulk density & Tapped density was in the between
0.281±0.041 to 0.318±.021 & 0.324±0.012 to 0.370±0.021. Compressibility index
was in range of 8.35±0.002 to 17.02±0.001. Hausner’s ratio was in the range of
1.091±0.031 to 1.205±0.012. These values indicate that the prepared granules
exhibited good flow properties. The results were shown in
Table 11.
The granules prepared by using Sodium starch glycolate were compressed
to tablets and tablets are tested for its physical characteristics. The thickness of the
tablets was in the range of 3.76±0.01 to 4.15±0.13. The friability of the tablets was
found to be in between 0.389 to 0.423. The hardness of the tablets was in the limit of
4.23±0.16 to 4.79±0.14. The weight variation of the tablets was in the range of
298±0.18 to 306±0.41. The wetting time & Disintegrating time lies in between 27 to
31 & 26 to 32. The drug content varied in between 98.41 to 101.76. The results are
shown in Table 12-13.
7.6 Invitro Dissolution Studies
On immersion in 0.1M HCl, pH 1.2 solution at 37±0.50 c  all  oral
dispersible tablets remained buoyant up to 30 min.
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7.6.1  Effect of Crospovidone on Drug Release
F1, F2, F3 were prepared by using Crospovidone as superdisintegrant and
the drug release for these formulation was given in the Table 14-16, Fig 17-19. The
release of drug for F1 at 5th & 30th minute was found to be 63.87% & 98.88%. The
release  of  drug  for  F2  at  5th minute was 67.31% and at 30th minute 97.15%. The
release of drug for F3 at 5th & 30th minute shows 61.05% & 99.18%
Crosspovidone due to their non-ionic nature, pyrolidone chemistry and
porous particle morphology, will rapidly absorb water via capillary action. During
tablet compaction, the highly compressible crospovidone particles become highly
deformed. The deformed particles come in contact with water that is wicked into the
tablet resulting in rapid volume expansion and hydrostatic pressure that cause tablet
disintegration. Due its high crosslink density, crospovidone swells rapidly in water
without gelling.
Other super disintegrants, like sodium starch glycolate and croscarmallose
sodium have lower crosslink density and as a result, form gels when fully hydrated,
particularly at higher use.
7.6.2 Effect of Croscarmellose Sodium on Drug Release
F4, F5, F6 were prepared by using Croscarmellose sodium as
superdisintegrant and the drug release for these formulation was given in the
Table 17-19, Fig 20-22. The release of drug for F4 at 5th minute was 65.81% and at
30th minute 94.87%. The release  of  drug  for  F5  at  5th shows 59.11% and at 30th
minute was found to be 96.74%. The release  of  drug  for  F6  at  5th minute & 30th
minute was 67.89% & 97.54%.
Croscarmellose sodium is an internally cross-linked sodium
carboxymethylcellulose for use as a disintegrant in pharmaceutical formulations.
The cross-linking reduces water solubility while still allowing the material to swell
and absorb many times its weight in water. As a result, it provides superior drug
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dissolution and disintegration characteristics, thus improving formulas subsequent
bioavailability.
7.6.3 Effect of Sodium Starch Glycolate on Drug Release
F7, F8, F9 were prepared by using Sodium starch glycolate as
superdisintegrant and the drug release for these formulation was given in the
Table 20-22, Fig 23-25. The release  of  drug  for  F7  at  5th minute was found to be
68.71% and at 30th minute shows 98.42%. The release of drug for F8 at 5th minute
was found to be 72.49% and at 30th minute was found to be 97.21%. The release of
drug for F9 at 5th minute & 30th minute has 69.11% & 97.86%.
Sodium starch glycolate generally elastic in nature  that they deform under
pressure. But, with the compression forces involved in tabletting will deform it more
to swell it higher. As a result it provides the dissolution.
7.7 Stability Study
Stability studies were conducted for the formulation F3. The stability study
was performed at 400 C±20 C/75% RH for a specific period of time. The tablets were
analysed for Disintegration time, Friability, Drug content, Hardness and In vitro
dissolution  studies.  The  overall  results  showed that  the  formulation  is  stable  at  the
above mentioned storage conditions shown in Table 24-25.
7.8 In vivo Studies
In vivo studies were done to find out the pharmacokinetic parameters of the
optimized formulation with the market product.
The Cmax for the innovator product was found to be 414.58ng/ml and for
the Tramaol hydrochloride (F3) was found to be 371.51ng/ml. The concentration of
the innovator product and Tramadol hydrochloride (F3) in plasma has nearly same.
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              The Tmax of the innovator product and Tramadol hydrochloride (F3) shows
at 2nd hour. AUC(0-t) for the innovator product and Tramadol HCl (F3) was 1014.2
ng-hr/ml & 8575.5 ng-hr/ml. AUMC??) shows 332.1 ng-hr*hr/ml & 2536.8 ng-
hr*hr/ml for innovator product and Tramadol HCl.
97
Summary
Chapter 1(P-1) begins with a general introduction presenting an overview
of oral dispersible tablets, in the part of the introduction the advantages,
disadvantages of oral dispersible tablets were discussed thoroughly. Introduction
shows the topic selected was worth investigating in the field of search.
Chapter 2(P-19) described the literature review carried out for selected
drug, superdisintegrants and design and evaluation of oral diapersible tablets.
Chapter 3(P-29) detailed the aim and objective of the present study.
Chapter 4(P-30) detailed the information of the selected drug, and also
excipients used in formulating oral dispersible tablets.
Chapter 5(44) described the plan of work.
Chapter 6(45) deals with the methodology followed for the preparation of
oral dispersible tablet after raw material analysis and drug excipient compatibility
studies. The detailed procedure for the preparation and evaluation of oral dispersible
tablet was mentioned.
Chapter 7(62) shows  the  results  and  detailed  discussion  of  all  the
formulations all the quantitative and qualitative parameters were analyzed. The raw
material analysis was carried out as per I.P and which met with specifications of I.P.
The Drug-Excipient compatibility study was done and found to have no interaction.
The physical charactersistics was done for all the formulations and the
results  were  found  to  be  satisfactory.  Invitro  dissolution  studies  were  done  for
Tramadol  HCL  oral  disintegrating  tablet  prepared  with  different  concentrations  of
Crospovidone, Croscarmellose sodium and SSG were compared and discussed.
Formulation F3 was found to have less disintegration time and maximum drug
release with in 30 mins.
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Stability studies were carried out for F3 by keeping the tablets at 400 C ± 20
C, 75% ± 5% RH for specific period of time. The physical parameters and drug
release of F3 were not altered much on storage conditions for specific period of time
which shows that the optimized formulation is found to be stable.
Invivo studies were done to find out the pharmacokinetic parameters of the
optimized formulation with the marketed product.
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Conclusion
The formulation containing 50mg of Tramadol hydrochloride was prepared
as orally dispersible tablet. These techniques are particularly useful for geriatrics and
pediatrics can be taken without the aid of water.
              The optimized formulation have consistent release profile to provide the
disintegration with in one minute by Crospovidone (F3).The short term stability
study also indicates no change in the physical characteristic of drug content.
               The comparision of pharmacokinetic parameters between the ODTs
Tramadol HCl and conventional tablet, showed no major changes in the
pharmacokinetic parameters. Hence, it can be concluded that the ODTs of Tramadol
HCl was successfully developed and evaluated.
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